In a vaccination study using TF conjugated to KLH in combination with an adjuvant therapy in ovarian cancer, a clear immune recognition of TF-glycoconjugates were found with anti-glycan antibody responses of IgM (n=9), IgG and also IgA subclasses [130]. Here, TF is linked to ovarian carcinoma.